免疫检查点抑制剂相关心肌炎:新型风险评分
该多中心回顾性注册研究纳入2014至2023年间17个国家748例因ICI心肌炎住院患者,构建并外部验证了预测30天不良复合结局的风险评分。活动性胸腺瘤、心脏肌肉症状、低QRS电压、LVEF<50%及肌钙蛋白升高幅度是独立预测因素,风险评分0分者30天结局发生率4%,≥4分者达81%。
要点
- ICI心肌炎患者30天主要复合结局发生率为33%,心肌毒性相关死亡13%。
- 活动性胸腺瘤、心脏肌肉症状、低QRS电压、LVEF<50%及肌钙蛋白升高幅度与不良结局独立相关。
- 基于上述因素的风险评分可区分低危与高危患者,并已在法国和美国队列中外部验证。
核心结论
- ICI相关心肌炎可表现为高发病率和高死亡率,其严重程度与肌钙蛋白升高幅度、胸腺瘤、低QRS电压、LVEF降低及心脏肌肉症状相关。
- 基于上述特征构建的风险评分表现良好,可用于风险分层。
研究设计与样本
- 多中心注册研究,回顾性收集2014至2023年间17个国家的数据。
- 纳入748例因ICI心肌炎住院的患者,67%为男性,年龄23至94岁。
- 采用多变量Cox回归模型确定主要复合结局的风险因素,并构建基于积分的预后风险评分,在法国和美国两个独立队列中进行外部验证。
主要发现
- 748例患者中,30天主要复合结局(严重心律失常、心力衰竭、呼吸肌衰竭和/或心肌毒性相关死亡)发生率为33%,心肌毒性相关死亡率为13%,总死亡率为17%。
- 多变量分析显示,主要复合结局与活动性胸腺瘤(HR 3.6,95%CI 1.7-7.7)、心脏肌肉症状(HR 2.6,95%CI 1.5-4.2)、就诊心电图低QRS电压(≤0.5 mV vs >1 mV,HR 1.9,95%CI 1.1-3.1)、LVEF<50%(HR 1.7,95%CI 1.1-2.6)及肌钙蛋白升高幅度(较正常上限升高20倍、200倍、2000倍时HR分别为1.8[95%CI 1.4-2.4]、2.9[95%CI 1.8-4.7]、4.6[95%CI 2.3-9.3])独立相关。
- 风险评分0分者30天主要结局发生率为4%,风险评分≥4分者发生率为81%。
- 风险评分在法国和美国两个独立队列中进行了外部验证;在法国外部队列中前瞻性使用该评分识别低风险患者,未接受免疫抑制治疗且无心肌毒性事件发生。
临床怎么用
- 对于ICI心肌炎住院患者,可依据活动性胸腺瘤、心脏肌肉症状、低QRS电压、LVEF<50%及肌钙蛋白升高幅度进行风险分层。
- 风险评分有助于识别低风险患者,可能避免不必要的免疫抑制治疗。
局限性
- 研究为回顾性注册设计,尽管采用了缺失数据填补和时间依赖协变量。
- 风险评分的外部验证队列规模及前瞻性应用数据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Immune checkpoint inhibitors (ICI) are associated with life-threatening myocarditis but milder presentations are increasingly recognized. The same autoimmune process that causes ICI myocarditis can manifest concurrent generalized myositis, myasthenia-like syndrome, and respiratory muscle failure. Prognostic factors for this 'cardiomyotoxicity' are lacking. The main aim of this study was to determine predictors and construct a risk score associated with negative outcomes in patients admitted for ICI myocarditis. METHODS: A multicentre registry collected data retrospectively from 17 countries between 2014 and 2023. A multivariable Cox regression model was used to determine risk factors for the primary composite outcome: time to severe arrhythmia, heart failure, respiratory muscle failure, and/or cardiomyotoxicity-related death. Covariates included demographics, comorbidities, cardiomuscular symptoms, diagnostics, and treatments. Time-dependent covariates were used, and missing data were imputed. A point-based prognostic risk score was derived and externally validated. RESULTS: In 748 patients (67% male, age 23-94 years), 30-day incidence of the primary composite outcome, cardiomyotoxic death, and overall death were 33%, 13%, and 17%, respectively. By multivariable analysis, the primary composite outcome was associated with active thymoma (hazard ratio [HR] 3.6, 95% confidence interval [CI] 1.7-7.7), presence of cardiomuscular symptoms (HR 2.6 [1.5-4.2]), low QRS voltage on presenting electrocardiogram (HR for ≤0.5 mV vs >1 mV 1.9 [1.1-3.1]), left ventricular ejection fraction (LVEF) < 50% (HR 1.7 [1.1-2.6]), and incremental troponin elevation (HR 1.8 [1.4-2.4], 2.9 [1.8-4.7], and 4.6 [2.3-9.3], for 20, 200, and 2000-fold above upper reference limit, respectively). A prognostic risk score developed using these parameters showed good performance; 30-day primary outcome incidence increased gradually from 4% (risk score = 0) to 81% (risk score ≥ 4). This risk score was externally validated in two independent French and US cohorts. This risk score was used prospectively in the external French cohort to identify low-risk patients who were managed with no immunosuppression resulting in no cardiomyotoxic events. CONCLUSIONS: ICI-associated myocarditis can manifest with high morbidity and mortality. Myocarditis severity is associated with magnitude of troponin, thymoma, low QRS voltage, depressed LVEF, and cardiomuscular symptoms. A risk score incorporating these features performed well. CLINICAL TRIAL REGISTRATION: NCT04294771 and NCT05454527.
引用
- Power JR, Dolladille C, Ozbay B, et al. Immune checkpoint inhibitor-associated myocarditis: a novel risk score. Eur Heart J. 2026. PMID: 40569849. doi:10.1093/eurheartj/ehaf315
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。